Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Century Therapeutics, Inc. (IPSC), a biological products company with a current market capitalization of $50 million, announced the results of its 2025 Annual Meeting of Stockholders, which took place on Sunday. The company’s stock, currently trading at $0.58, has experienced significant volatility, declining over 80% in the past year. The meeting, held virtually, addressed two primary proposals involving the election of directors and the ratification of the company’s independent registered public accounting firm. According to InvestingPro analysis, the company maintains a FAIR financial health score, with particularly strong liquidity indicated by a current ratio of 11.7.
In the first proposal, stockholders elected Daphne Quimi and Carlo Rizzuto, Ph.D., as Class I directors to serve on the company’s board until the 2028 Annual Meeting of Stockholders. The election results were as follows: Quimi received 52,593,454 votes for and 4,437,555 withheld, while Rizzuto received 51,373,990 votes for and 5,657,019 withheld. Both candidates experienced 15,072,004 broker non-votes.
The second proposal concerned the ratification of Ernst & Young LLP as Century Therapeutics’ independent registered public accounting firm for the fiscal year 2025. This proposal was overwhelmingly approved, with 71,768,193 votes for, 302,484 against, and 32,336 abstentions. There were no broker non-votes for this proposal.
The meeting’s outcomes are considered crucial for the company’s governance and financial oversight. Century Therapeutics, based in Philadelphia, Pennsylvania, is incorporated in Delaware and is listed on the Nasdaq Global Select Market under the ticker symbol IPSC. As of April 16, 2025, the record date for the Annual Meeting, Century Therapeutics had 86,158,758 outstanding shares of common stock.
The company has been identified as an emerging growth company, and it has elected to use the extended transition period for complying with new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Analysts maintain an optimistic outlook, with price targets ranging from $2 to $7, suggesting potential upside from current levels. InvestingPro subscribers can access detailed financial analysis, including 12 additional ProTips and comprehensive valuation metrics to better understand the company’s growth potential.
This report is based on Century Therapeutics’ recent SEC filing and provides a factual summary of the key outcomes of the Annual Meeting as they pertain to shareholders and the broader investment community. The company’s revenue growth forecast for FY2025 stands at 15.57%, while maintaining a beta of 1.78, indicating higher volatility compared to the broader market.
In other recent news, Century Therapeutics has made several strategic updates that have caught the attention of analysts and investors. The company announced the discontinuation of its CNTY-101 program in Phase 1 trials for B cell lymphomas due to unmet transformative criteria, which led H.C. Wainwright to revise its price target from $5.00 to $2.00, though it maintained a Buy rating. Guggenheim also adjusted its price target from $12.00 to $5.00, while keeping a Buy rating, following Century’s fiscal year 2024 results and pipeline re-prioritization. Despite these adjustments, Century Therapeutics continues to explore the potential of CNTY-101 in autoimmune diseases, with the first patient enrolled in the Phase I CALiPSO-1 trial. The company aims to start dosing soon, signaling ongoing efforts to expand its therapeutic applications. Additionally, Century has showcased advancements in its AlloEvasion technology, now in its fifth generation, which is designed to enhance the effectiveness of cell therapies. H.C. Wainwright remains optimistic about the preclinical data, noting the potential for future clinical impact. Investors are watching closely as Century plans to present additional data in 2025, which could influence its strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.